News
A Roth IRA might not be the flashiest way to spend your summer job money, but saving even a small portion of your paycheck could net...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on...
News
This article was written by Follow Author and entrepreneur. My articles typically cover macroeconomic trends, portfolio strategy, value investing, and behavioral finance. I like...
News
This article was written by Follow Dhierin-Perkash Bechai is an aerospace, defense and airline analyst. Dhierin runs the investing group The Aerospace Forum, whose...
News
This article was written by B.A., M.A., University of Pennsylvania,; M.A., (Oxon.); Ph.D. Princeton University Currently CEO of WWS Swiss Financial Consulting SA Analyst’s...
News
America’s car dealers ended the second quarter with more than 92,000 electric vehicles on dealer lots awaiting sale. A year ago, they had 21,000....
News
Introduction I always like to start my articles, when I can, by reviewing any previous coverage I’ve had of a stock. In Fidelity National...
News
The average borrower taking out a used car loan in the first quarter of 2023 borrowed 125% of the value of the car they...
News
With the S&P 500 hovering around 12-month highs despite macro jitters, a common question investors are asking is: is it too late to get...
News
Amid stiff competition in a generally saturated market, American oral care giant Colgate-Palmolive (NYSE:CL) has delivered marginal growth over the past several years. A...
News
These 3 are smaller than the competition, make no mistake they bring a lot to the table I used the words revenge of the...
News
Introduction Aldeyra Therapeutics (NASDAQ:ALDX) is a biotech firm focused on creating therapies for immune-mediated diseases. Their groundbreaking RASP (reactive aldehyde species) pharmaceutical platform targets...
News
On July 6, 2023, the Food and Drug Administration granted full approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALF, OTCPK:ESAIY) anti-amyloid antibody drug Leqembi. For...
